Publikationen

2022:

Muin DA, Pfeifer B, Helmer H, Oberaigner W, Leitner H, Kiss H, et al. Universal gestational diabetes screening and antepartum stillbirth rates in Austria-A population-based study. Acta Obstet Gynecol Scand. 2022;101(4):396-404.

2021:

Windsperger K, Kiss H, Oberaigner W, Leitner H, Binder F, Muin DA, et al. Exposure to night-time light pollution and risk of prolonged duration of labor: A nationwide cohort study. Birth. 2021.

Schaffner M, Rochau U, Stojkov I, Qerimi Rushaj V, Völzke H, Marckmann G, et al. Barriers Against Prevention Programs for Iodine Deficiency Disorders in Europe: A Delphi Study. Thyroid : official journal of the American Thyroid Association. 2021;31(4):649-57.

Schaffner M, Rochau U, Mühlberger N, Conrads-Frank A, Qerimi Rushaj V, Sroczynski G, et al. The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany. Endocr Connect. 2021;10(1):1-12.

Schaffner M, Mühlberger N, Conrads-Frank A, Qerimi Rushaj V, Sroczynski G, Koukkou E, et al. Benefits and Harms of a Prevention Program for Iodine Deficiency Disorders: Predictions of the Decision-Analytic EUthyroid Model. Thyroid : official journal of the American Thyroid Association. 2021;31(3):494-508.

Rossboth S, Rossboth B, Schoenherr H, Lechleitner M, Oberaigner W. Risk factors for diabetic foot complications among patients with type 2 diabetes in Austria-A registry-based retrospective cohort study. Endocrinol Diabetes Metab. 2021;4(4):e00286.

Rossboth S, Rossboth B, Schoenherr H, Ciardi C, Lechleitner M, Oberaigner W. Diabetic foot complications-lessons learned from real-world data derived from a specialized Austrian hospital. Wiener klinische Wochenschrift. 2021.

Rossboth S, Lechleitner M, Oberaigner W. Risk factors for diabetic foot complications in type 2 diabetes-A systematic review. Endocrinol Diabetes Metab. 2021;4(1):e00175.

Lechner R, Lazzeri M, Oberaigner W, Nardelli P, Roth T, Köglberger P, et al. Does the type of surgical approach affect the clinical outcome of total knee arthroplasty? Orthopade. 2021.

Köglberger P, Wurm A, Coraça-Huber D, Krismer M, Oberaigner W, Liebensteiner M. High range of motion in the first ten postoperative days after TKA does not predict superior outcome in the long run. Arch Orthop Trauma Surg. 2021.

Brenner S, Daikeler R, Oberaigner W, Stummer H. [Cardiovascular risk management in type-2 diabetes: Is the patients' cardiovascular risk adequately considered in type-2 specialist diabetes care?]. Z Evid Fortbild Qual Gesundhwes. 2021;167:6-14.

2020: Rossboth S, Lechleitner M, Oberaigner W. Risk factors for diabetic foot complications in type 2diabetes—A systematic review. Endocrinology, Diabetes & Metabolism. 2020.

Liebensteiner M, Köglberger P, Ruzicka A, Giesinger JM, Oberaigner W, Krismer M. Unicondylar vs. total knee arthroplasty in medial osteoarthritis: a retrospective analysis of registry data and functional outcome. Arch Orthop Trauma Surg. 2020;140(4):545-9.

Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koenig D, Poelzl K, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018. BMJ Open Diabetes Res Care. 2020;8(1).

Brenner S, Oberaigner W, Stummer H. In guidelines physicians trust? Physician perspective on adherence to medical guidelines for type 2 diabetes mellitus. Heliyon. 2020;6(8):e04803.

Brenner S, Oberaigner W, Stummer H. In guidelines physicians trust? Physician perspective on adherence to medical guidelines for type 2 diabetes mellitus. Heliyon. 2020;6(e04803).

Gothe H, Matteucci Gothe R, Arvandi M, Hintringer K, Toell T, Oberaigner W, Rajsic S, Kugler J, Kiechl S, Willeit J, Siebert U. Linkage of Clinical and Claims Data in the Evaluation of Post-Stroke Care - SeDaStro: Experiences from the Tyrolian StrokeCard Program. Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)). 2020; 82(2):122-30. [A2]

Sroczynski G, Esteban E, Widschwendter A, Oberaigner W, Borena W, von Laer D, Hackl M, Endel G, Siebert U. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria. International journal of cancer. 2020; 147(4):1131-42. [A1]

2019

Jahn B, Sroczynski G, Bundo M, Muhlberger N, Puntscher S, Todorovic J, Rochau U, Oberaigner W, Koffijberg H, Fischer T, Schiller-Fruehwirth I, Ofner D, Renner F, Jonas M, Hackl M, Ferlitsch M, Siebert U, Austrian Colorectal Cancer Screening Model G. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. BMC Gastroenterol. 2019; 19(1):209. [A2]

2017

108.    Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. The Lancet Haematology. 2017 May;4(5):e202-e17

109.    Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sanchez MJ, et al. Geographical variability in survival of European children with central nervous system tumours. European journal of cancer (Oxford, England : 1990). 2017 Jul 06;82:137-48.

110.    Granbichler CA, Oberaigner W, Kuchukhidze G, Ndayisaba JP, Ndayisaba A, Taylor A, et al. Decrease in mortality of adult epilepsy patients since 1980: lessons learned from a hospital-based cohort. European journal of neurology. 2017 May;24(5):667-72.

111.    Heidegger I, Oberaigner W, Horninger W, Pichler R. High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: A 10-year single-center experience. Urologic oncology. 2017 Apr;35(4):152 e1- e5.

112.    Lunger L, Melmer A, Oberaigner W, Leo M, Juchum M, Polzl K, et al. Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015. Wiener klinische Wochenschrift. 2017 Jan;129(1-2):46-51.

113.    Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, et al. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. European journal of cancer (Oxford, England : 1990). 2017 Jan;70:111-21.

114.    Muhlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, et al. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model. BMC public health. 2017 Jun 26;17(1):596.

115.    Oberaigner W, Geiger-Gritsch S, Edlinger M, Daniaux M, Knapp R, Hubalek M, et al. Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria. Breast (Edinburgh, Scotland). 2017 Jun;33:178-82.

116.    Oberaigner W, Haring C, Sperner-Unterweger B, Niederkrotenthaler T, Waldhor T. Letter to the Editor Re: "Suicide among 915,303 Austrian cancer patients: Who is at risk? Benjamin Vyssoki, Andreas Gleiss, Ian R.H. Rockett, Monika Hackl, Barbara Leitner, Gernot Sonneck, Nestor D. Kapusta [J. Affective Disord. 175 (2015)287-291]". Journal of affective disorders. 2017 Jan 01;207:320.

117.    Pichler R, Tulchiner G, Oberaigner W, Schaefer G, Horninger W, Brunner A, et al. Effect of Urinary Cytology for Detecting Recurrence in Remnant Urothelium After Radical Cystectomy: Insights From a 10-year Cytology Database. Clinical genitourinary cancer. 2017 Mar 30.

118.    Zenzmaier C, Leitner H, Brezinka C, Oberaigner W, Konig-Bachmann M. Maternal and neonatal outcomes after induction of labor: a population-based study. Archives of gynecology and obstetrics. 2017 May;295(5):1175-83.

 

2016

105.    Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT](NHL-14). European journal of cancer (Oxford, England : 1990). 2016 May;58:112-21.

106.    Monshi B, Vujic M, Kivaranovic D, Sesti A, Oberaigner W, Vujic I, et al. The burden of malignant melanoma--lessons to be learned from Austria. European journal of cancer (Oxford, England : 1990). 2016 Mar;56:45-53.

107.    Polsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, et al. High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing. European journal of human genetics : EJHG. 2016 Feb;24(2):258-62.

 

2015

95.       Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (London, England). 2015 Mar 14;385(9972):977-1010.

96.       Daniaux M, De Zordo T, Santner W, Amort B, Koppelstatter F, Jaschke W, et al. Dual-energy contrast-enhanced spectral mammography (CESM). Archives of gynecology and obstetrics. 2015 Oct;292(4):739-47.

97.       Geiger-Gritsch S, Oberaigner W, Muhlberger N, Siebert U, Ladurner M, Klocker H, et al. Patient-reported urinary incontinence and erectile dysfunction following radical prostatectomy: results from the European Prostate Centre Innsbruck. Urologia internationalis. 2015;94(4):419-27.

98.       Granbichler CA, Oberaigner W, Kuchukhidze G, Bauer G, Ndayisaba JP, Seppi K, et al. Cause-specific mortality in adult epilepsy patients from Tyrol, Austria: hospital-based study. Journal of neurology. 2015 Jan;262(1):126-33.

99.       Kocher F, Finkenstedt A, Fiegl M, Graziadei I, Gamerith G, Oberaigner W, et al. Liver Transplantation-Associated Lung Cancer: Comparison of Clinical Parameters and Outcomes. Clinical lung cancer. 2015 Sep;16(5):e75-81.

100.    Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung cancer (Amsterdam, Netherlands). 2015 Feb;87(2):193-200.

101.    Krismer M, Nogler M, Huber D, Oberaigner W. Cemented ABG-II prosthesis: 5-year results. Hip international : the journal of clinical and experimental research on hip pathology and therapy. 2015 Jan-Feb;25(1):56-60.

102.    Muhlberger N, Kurzthaler C, Iskandar R, Krahn MD, Bremner KE, Oberaigner W, et al. The ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening. Medical decision making : an international journal of the Society for Medical Decision Making. 2015 Aug;35(6):758-72.

103.    Nagel G, Oberaigner W, Peter RS, Ulmer H, Concin H. Evaluation of a mammography screening program within the population-based Vorarlberg Health Monitoring & Prevention Program (VHM&PP). Cancer epidemiology. 2015 Dec;39(6):812-8.

104.    Pinter B, Diem-Zangerl A, Wenning GK, Scherfler C, Oberaigner W, Seppi K, et al. Mortality in Parkinson's disease: a 38-year follow-up study. Movement disorders : official journal of the Movement Disorder Society. 2015 Feb;30(2):266-9.

 

2014

85.       De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. The Lancet Oncology. 2014 Jan;15(1):23-34.

86.       Edlinger M, Ulmer H, Cvancarova M, Oberaigner W. Site-specific proportion cured models applied to cancer registry data. Cancer causes & control : CCC. 2014 Mar;25(3):365-73.

87.       Fiegl M, Pircher A, Waldthaler C, Gamerith G, Kocher F, Pall G, et al. Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patients. Lung cancer (Amsterdam, Netherlands). 2014 May;84(2):168-74.

88.       Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. The Lancet Oncology. 2014 Jan;15(1):35-47.

89.       Muhlberger N, Heijnsdijk EA, Kurzthaler C, Iskandar R, Krahn MD, Bremner K, et al. The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014 Nov;17(7):A559.

90.       Mutz-Dehbalaie I, Scheier M, Jerabek-Klestil S, Brantner C, Windbichler GH, Leitner H, et al. Perinatal mortality and advanced maternal age. Gynecologic and obstetric investigation. 2014;77(1):50-7.

91.       Oberaigner W, Ebenbichler C, Oberaigner K, Juchum M, Schonherr HR, Lechleitner M. Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. BMC public health. 2014 Oct 10;14:1058.

92.       Oberaigner W, Geiger-Gritsch S. Prediction of cancer incidence in Tyrol/Austria for year of diagnosis 2020. Wiener klinische Wochenschrift. 2014 Oct;126(19-20):642-9.

93.       Oberaigner W, Sperner-Unterweger B, Fiegl M, Geiger-Gritsch S, Haring C. Increased suicide risk in cancer patients in Tyrol/Austria. General hospital psychiatry. 2014 Sep-Oct;36(5):483-7.

94.       Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. The Lancet Oncology. 2014 Aug;15(9):931-42.

 

2013

83.       Oberaigner W, Leitner H, Oberaigner K, Marth C, Pinzger G, Concin H, et al. Migrants and obstetrics in Austria--applying a new questionnaire shows differences in obstetric care and outcome. Wiener klinische Wochenschrift. 2013 Jan;125(1-2):34-40.

84.       Trinka E, Bauer G, Oberaigner W, Ndayisaba JP, Seppi K, Granbichler CA. Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. Epilepsia. 2013 Mar;54(3):495-501.

 

2012

77.       Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012 Sep;97(9):1431-8.

78.       Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta oncologica (Stockholm, Sweden). 2012 Apr;51(4):441-53.

79.       Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G, et al. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. International journal of public health. 2012 Feb;57(1):57-62.

80.       Sant M, Minicozzi P, Lagorio S, Borge Johannesen T, Marcos-Gragera R, Francisci S. Survival of European patients with central nervous system tumors. International journal of cancer. 2012 Jul 01;131(1):173-85.

81.       Sterlacci W, Savic S, Schmid T, Oberaigner W, Auberger J, Fiegl M, et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. American journal of clinical pathology. 2012 Jun;137(6):946-56.

82.       Sterlacci W, Stockinger R, Schmid T, Bodner J, Hilbe W, Waldthaler C, et al. The elderly patient with surgically resected non-small cell lung cancer--a distinct situation? Experimental gerontology. 2012 Mar;47(3):237-42.

 

2011

71.       Leitner H, Bose-O'Reilly S, Oberaigner W, Mark M, Brezinka C, Siebert U. [Perinatal mortality by mother's country of origin in Tyrol 2000-2008]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)). 2011 Aug;73(8-9):469-76.

72.       Oberaigner W, Buchberger W, Frede T, Daniaux M, Knapp R, Marth C, et al. Introduction of organised mammography screening in Tyrol: results of a one-year pilot phase. BMC public health. 2011 Feb 09;11:91.

73.       Oberaigner W, Daniaux M, Geiger-Gritsch S, Knapp R, Siebert U, Buchberger W. Introduction of organised mammography screening in Tyrol: results following first year of complete rollout. BMC public health. 2011 Aug 30;11:673.

74.       Oberaigner W, Siebert U. Do women with cancer have better survival as compared to men after adjusting for staging distribution? European journal of public health. 2011 Jun;21(3):387-91.

75.       Sterlacci W, Tzankov A, Veits L, Oberaigner W, Schmid T, Hilbe W, et al. The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics. American journal of clinical pathology. 2011 Apr;135(4):611-8.

76.       Zigon G, Berrino F, Gatta G, Sanchez MJ, van Dijk B, Van Eycken E, et al. Prognoses for head and neck cancers in Europe diagnosed in 1995-1999: a population-based study. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Jan;22(1):165-74.

2010

60.       Manual for coding and reporting haematological malignancies. Tumori. 2010 Jul-Aug;96(4):i-A32.

61.       Apostol I, Baban A, Nicula F, Suteu O, Coza D, Amati C, et al. Cervical cancer assessment in Romania under EUROCHIP-2. Tumori. 2010 Jul-Aug;96(4):545-52.

62.       Diem-Zangerl A, Seppi K, Oberaigner W, Poewe W. Mortality in Parkinson's disease, a 20-year follow-up study. Movement disorders : official journal of the Movement Disorder Society. 2010 Apr 15;25(5):661-2.

63.       Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, et al. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. Annals of hematology. 2010 Mar;89(3):273-82.

64.       Oberaigner W, Buchberger W, Frede T, Knapp R, Marth C, Siebert U. Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening. BMC public health. 2010 Feb 20;10:86.

65.       Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, et al. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Sep;5(9):1325-36.

66.       Strasak AM, Goebel G, Concin H, Pfeiffer RM, Brant LJ, Nagel G, et al. Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancer. Cancer research. 2010 May 01;70(9):3586-93.

67.       Valerianova Z, Panayotova Y, Amati C, Baili P. Cervical cancer screening in Bulgaria--past and present experience. Tumori. 2010 Jul-Aug;96(4):538-44.

68.       Veerus P, Arbyn M, Amati C, Paolo B. Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Tumori. 2010 Jul-Aug;96(4):524-8.

69.       Viberga I, Engele L, Baili P. Past, present and future of the cervical cancer screening in Latvia. Tumori. 2010 Jul-Aug;96(4):529-37.

70.       Weber B, Schwabegger AH, Oberaigner W, Rumer-Moser A, Steiner H. Incidence of perinatal complications in children with premature craniosynostosis. Journal of perinatal medicine. 2010 May;38(3):319-25.

2009

43.       Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Capocaccia R. Comparative cancer survival information in Europe. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):901-8.

44.       Brenner H, Francisci S, de Angelis R, Marcos-Gragera R, Verdecchia A, Gatta G, et al. Long-term survival expectations of cancer patients in Europe in 2000-2002. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):1028-41.

45.       Ciccolallo L, Licitra L, Cantu G, Gatta G. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral oncology. 2009 Aug;45(8):669-74.

46.       De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Belot A, et al. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):909-30.

47.       Diem-Zangerl A, Seppi K, Wenning GK, Trinka E, Ransmayr G, Oberaigner W, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Movement disorders : official journal of the Movement Disorder Society. 2009 Apr 30;24(6):819-25.

48.       Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009 Oct;9(10):2355-61.

49.       Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Allemani C, et al. The cure of cancer: a European perspective. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):1067-79.

50.       Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):992-1005.

51.       Marth C, Hiebl S, Oberaigner W, Winter R, Leodolter S, Sevelda P. Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Jan;19(1):94-102.

52.       Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):1017-27.

53.       Oberaigner W, Siebert U. Are survival rates for Tyrol published in the Eurocare studies biased? Acta oncologica (Stockholm, Sweden). 2009;48(7):984-91.

54.       Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Allemani C, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):1006-16.

55.       Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, et al. Multiple tumours in survival estimates. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):1080-94.

56.       Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):931-91.

57.       Strasak AM, Lang S, Kneib T, Brant LJ, Klenk J, Hilbe W, et al. Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 men. Annals of epidemiology. 2009 Jan;19(1):15-24.

58.       Strasak AM, Pfeiffer RM, Brant LJ, Rapp K, Hilbe W, Oberaigner W, et al. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Jun;20(6):1113-20.

59.       Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. European journal of cancer (Oxford, England : 1990). 2009 Apr;45(6):1042-66.

2008

35.       Baili P, Micheli A, De Angelis R, Weir HK, Francisci S, Santaquilani M, et al. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori. 2008 Sep-Oct;94(5):658-68.

36.       Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU international. 2008 Apr;101(7):809-16.

37.       Rapp K, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, et al. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Apr;19(4):641-8.

38.       Sant M, Allemani C, De Angelis R, Carbone A, de Sanjose S, Gianni AM, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. European journal of cancer (Oxford, England : 1990). 2008 Mar;44(4):579-87.

39.       Strasak AM, Kelleher CC, Brant LJ, Rapp K, Ruttmann E, Concin H, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. International journal of cardiology. 2008 Apr 10;125(2):232-9.

40.       Strasak AM, Pfeiffer RM, Klenk J, Hilbe W, Oberaigner W, Gregory M, et al. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. International journal of cancer. 2008 Oct 15;123(8):1902-6.

41.       Strasak AM, Rapp K, Brant LJ, Hilbe W, Gregory M, Oberaigner W, et al. Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer research. 2008 May 15;68(10):3970-7.

42.       Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Survival in patients with uveal melanoma in Europe. Archives of ophthalmology (Chicago, Ill : 1960). 2008 Oct;126(10):1413-8.

2007

31.       Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner W, Strauss R. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. Journal of hepatology. 2007 Jul;47(1):31-6.

32.       Oberaigner W. Errors in survival rates caused by routinely used deterministic record linkage methods. Methods of information in medicine. 2007;46(4):420-4.

33.       Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H, et al. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Nov;18(11):1893-7.

34.       Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H, et al. Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer causes & control : CCC. 2007 Nov;18(9):1021-9.

2006

26.       Darby S, Hill D, Deo H, Auvinen A, Barros-Dios JM, Baysson H, et al. Residential radon and lung cancer--detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. Scandinavian journal of work, environment & health. 2006;32 Suppl 1:1-83.

27.       Mitterlechner T, Fiegl M, Muhlbock H, Oberaigner W, Dirnhofer S, Tzankov A. Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. Journal of clinical pathology. 2006 Jan;59(1):48-55.

28.       Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. American journal of epidemiology. 2006 Aug 15;164(4):376-84.

29.       Oberaigner W, Stuhlinger W. Influence of department volume on cancer survival for gynaecological cancers--a population-based study in Tyrol, Austria. Gynecologic oncology. 2006 Nov;103(2):527-34.

30.       Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006 May;49(5):945-52.

2005

21.       Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ (Clinical research ed). 2005 Jan 29;330(7485):223.

22.       Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, et al. Long-term results of dose density therapy in patients with aggressive lymphoma. Annals of hematology. 2005 Apr;84(4):217-22.

23.       Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, et al. Screening for prostate cancer: updated experience from the Tyrol study. The Canadian journal of urology. 2005 Feb;12 Suppl 1:7-13; discussion 92-3.

24.       Oberaigner W, Stuhlinger W. Record linkage in the Cancer Registry of Tyrol, Austria. Methods of information in medicine. 2005;44(5):626-30.

25.       Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. British journal of cancer. 2005 Oct 31;93(9):1062-7.